Entries by Ayal Ronen

$580,000,000 CDMRP Awards Appropriated for 2014!

The Fiscal Year 2014 Department of Defense Appropriations Act will fund some$580,000,000 through the Congressionally Directed Medical Research Programs (CDMRP). Programs range from Oncology, ALS, Autism, through MS, Orthopedic research and more. Program Announcements will be issued during 2014, Stay Tuned!  The FreeMind Group has extensive experience in assisting clients in completing and winning such complex […]

/by

9th Annual Non-dilutive Funding Summit

[vc_row][vc_column width=”1/1″][pt_heading h=”h3″ heading=” Join over 250 life science industry leaders in a full day of non-dilutive funding activities at the 9th Annual Non-dilutive Funding Summit, taking place on Wednesday January 15th, 2014 at the Nikko Hotel San Francisco. ” text_align=”align-left”][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][vc_separator][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][pt_text text_align=”align-left”] The summit is proud to host Dr Jodi Black of the […]

/by

CEOCFO Magazine Interviews Ram May-Ron, FreeMind’s Managing Partner – Securing Non-Dilutive Source Funding for Life Science Industry Companies

Interview conducted by: Lynn Fosse, Senior Editor, CEOCFO Magazine, Published – October 14, 2013 [PDF Article] CEOCFO: Mr. May-Ron, what is the vision and concept at FreeMind Group? Mr. May-Ron: What we are trying to do is just one thing. Within the life science industry there are three main sources of funding globally as well as the […]

/by

Harvard i-lab | Presentation by Ram May-Ron, Managing Partner FreeMind; Non-Dilutive Funding for Early-Stage Life Sciences Companies and Beyond

Presentation at the Harvard Innovation Lab by Ram May-Ron, Managing Partner FreeMind. Synopsis: Explore ways to maximize funding for science companies from non-dilutive funding sources such as NIH, DOD SBIRs (Small Business Innovation Research) and other federal and private sources. Learn about successful strategies for building a multi-submission strategy and academia-industry collaborations in the pursuit of […]

/by

THE 4TH GALIEN FORUM EVENT

The 2013 Galien Forum will take place at the Alexandria Center for Life Science on the morning of October 22nd, 2013, and will feature round table debates focusing on critical global healthcare issues and challenges. The annual life science Forum is rapidly becoming a leading event for discussing issues of innovation in the industry. The […]

/by

ASSOBIOTEC – FREEMIND GROUP PRESENTATION: NIH/DOD Non-dilutive Funding Opportunities; non-US applicants are welcome!

Currently, the National Institutes of Health (NIH) are actively funding 1,124 projects amounting to $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations and partnerships between domestic and foreign entities, the funded R&D dollars outside the US even exceed the above. In this presentation Ayal Ronen, […]

/by

National Science Foundation (NSF) – SBIR and STTR Programs

The National Science Foundation (NSF) has recently updated the SBIR and STTR programs for the upcoming December 2nd and 4th deadlines, respectively. Areas of interest cover Biological and Biomedical Technologies and are a fantastic source of funding for early-stage projects. Some $42,000,000 will be awarded through these mechanisms to roughly 250 awards.   ABOUT THE NSF The National […]

/by

NIH Director Francis Collins – Smash hit “Sequester Blues”

Pumping Congress to find a way to wipe away the sequester cuts, or at the very least exempt NIH or restore funding another way, has become an important part of NIH Director Francis Collins’ job, which also includes singing the blues about the sequestration. Collins says he has probably personally visited with more than 100 members […]

/by

Webinar: Medical Device Non-Dilutive Funding: Trends & Opportunities

In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies. The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation. In the upcoming […]

/by